ADMA Biologics/$ADMA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Ticker

$ADMA
Primary listing

Industry

Biotechnology

Employees

685

ISIN

US0008991046

ADMA Biologics Metrics

BasicAdvanced
$4.4B
21.87
$0.84
0.57
-

What the Analysts think about ADMA Biologics

Analyst ratings (Buy, Hold, Sell) for ADMA Biologics stock.

Bulls say / Bears say

ADMA Biologics reported a 65% year-over-year increase in total revenue for FY 2024, reaching $426.5 million, driven primarily by increased sales of ASCENIV and BIVIGAM. (admabiologics.com)
The company achieved its first GAAP net income of $197.7 million in 2024, a significant turnaround from a net loss of $28.2 million in 2023, indicating strong financial health. (admabiologics.com)
ADMA secured long-term high-titer plasma supply contracts expected to support ASCENIV revenue growth through the late 2030s, ensuring a stable supply chain for its key product. (admabiologics.com)
Two customers accounted for approximately 72% of ADMA's consolidated revenues in 2024, indicating a high customer concentration risk. (panabee.com)
The company's reliance on non-GAAP financial measures may obscure true financial performance, potentially leading to misunderstandings among investors regarding actual profitability. (nasdaq.com)
Ongoing concerns about product withdrawals could impact future revenue stability and customer confidence in ADMA's offerings. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

ADMA Biologics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ADMA Biologics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ADMA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs